R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

Leukemia. 2010 Mar;24(3):652-4. doi: 10.1038/leu.2009.240. Epub 2009 Dec 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Male
  • Middle Aged
  • Rituximab
  • Tumor Suppressor Protein p53 / physiology
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Tumor Suppressor Protein p53
  • Cytarabine
  • Rituximab
  • Dexamethasone
  • Vidarabine
  • fludarabine
  • Cisplatin

Supplementary concepts

  • DHAP protocol